Navigation Links
Eisai/Pfizer's Aricept Owns a Dominating 42.4% Patient Share for First-Line Treatment of Alzheimer's Disease
Date:2/4/2008

Physician Familiarity and its Better Side-Effect/Safety Profile are Driving

Aricept Prescription Rates, According to a New Report from Decision

Resources

WALTHAM, Mass., Feb. 4 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Eisai/Pfizer's Aricept owns a dominating 42.4% patient share for first-line treatment of newly diagnosed Alzheimer's disease patients. The new report entitled Treatment Algorithms in Alzheimer's Disease finds that the reasons for favoring Aricept differ between primary care physicians and neurologists. Primary care physicians prefer Aricept over other acetylcholinesterase inhibitors (AChEIs) largely because of their familiarity with the agent, while neurologists cite Aricept's side-effect/safety profile and easier titration (the dosing schedule needed for a patient to receive full therapeutic doses of a drug).

The report finds that, in first-line treatment, Aricept holds a 42.4% patient share. The two twice-per-day AChEIs -- Novartis's Exelon and Shire/Janssen/Ortho-McNeil's Razadyne hold only 2.8% and 1.4% shares, respectively. Aricept's first-line patient share also far exceeds that of the newer formulations of those two drugs, including the once-daily formulation of Razadyne, Razadyne ER.

"Aricept's critical attribute of once-daily administration was unique until the launch of Razadyne ER in 2005," said Madhuri Borde, Ph.D., analyst at Decision Resources. "However, our survey revealed that physicians prescribe Aricept more than any other AChEI, in large part because of their comfort level with the drug, and because primary care physicians have been slow to move to Razadyne ER."

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics(R) to p
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
2. The LANCET Published ENDORSE, the Largest Multinational Study Showing That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE Prophylaxis
3. FDA Grants Priority Review for Schering-Ploughs Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
4. Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy
5. Breakthrough Opportunity for Improving Patient Health
6. Cryolife Once Again Severely Maims an Innocent Knee Surgery Patient
7. Physicians Practice, Loma Linda Partner to Improve Patient Care in Southern California
8. Difficult to Treat Erectile Dysfunction Patients
9. TAP Pharmaceutical Products Inc. Files New Drug Application for TAK-390MR in Patients with Acid-Related Disorders
10. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
11. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Oct. 30, 2014  Ardelyx, Inc. (NASDAQ: ... on cardio-renal, gastrointestinal and metabolic diseases, today announced ... results on Thursday, November 6, 2014. Following the ... live conference call and webcast at 4:30pm ET ... a business update. The live webcast ...
(Date:10/30/2014)... On October 26th at the Mid ... leading applied stem cell research scientist Neil Riordan, ... talks on New Techniques for Enhancing Stem Cell ... Cells. , Dr. Riordan focused on historical medical ... AlphaGEMS that include: wound healing; inflammation and pain ...
(Date:10/30/2014)... James Sherley says he has been working towards ... technology since his days as a principal investigator at the ... 1990’s. Sherley founded the ASCTC as a new Boston ... intellectual property developed in Sherley’s research over the years since ... Technology (MIT), and more recently as a senior scientist at ...
(Date:10/30/2014)... Avure Technologies celebrates a year of success and the one-year ... of high volume High Pressure Processing (HPP) systems. , “We’re ... PackExpo this year, which is where we first announced the ... CEO at Avure. “Sales of the new Avure machine are ... challenges of market demand for higher throughput. We sold our ...
Breaking Biology Technology:Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 2Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 3Riordan-McKenna Institute Founders, Neil Riordan, PhD and Orthopedic Surgeon, Dr. Wade McKenna Present at the Mid American Regenerative and Cellular Medicine Showcase 4Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 2In High Demand: New High Pressure Processing (HPP) System with Maximum Throughput Drives Strong Sales 3
... by Columbia Business School Professor Frank Lichtenberg, Courtney ... Healthcare and Pharmaceutical Management Program, and Bhaven Sampat, ... and Management at the Mailman School of Public ... of direct and indirect government support in research ...
... 2011  BioStorage Technologies, a global provider of comprehensive sample ... sample intelligence and tracking for the bioscience industry, is ... "CFO of the Year" by the Indianapolis Business Journal ... the private companies category with $100 million or less ...
... Dec. 15, 2011 Kevin W. Sharer, chairman and chief ... 2000, has announced his plan to retire from the Company ... to Amgen.  To facilitate an orderly transition process, Sharer will ... as chairman of the Company,s Board of Directors until December ...
Cached Biology Technology: The respective roles of the public and private sectors in pharmaceutical innovation 2BioStorage Technologies' Mike Reffeitt Named "CFO of the Year" by Indianapolis Business Journal 2Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 2Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012 3
(Date:10/30/2014)... October 2014 Biological membranes are mainly composed of ... of solution ions onto lipid membranes helps clarify ... study provides a quantitative description of the equilibria ... Kotyńska and Zbigniew Figaszewski from the University of ... describing these findings, just published in EPJ ...
(Date:10/29/2014)... 2014, Beaverton, OR) New research presented at ... Conference in Houston, TX showed for the first ... infection in women using a readily available nutritional ... presented by Dr. Judith A. Smith, Pharm.D., associate ... Reproductive Sciences at The University of Texas Health ...
(Date:10/29/2014)... nanoparticles is all the rage. Thousands of scientists worldwide ... of whether titanium dioxide nanoparticles from sun creams can ... carbon nanotubes from electronic products are as hazardous for ... nanoparticles in food can get into the blood via ... research funds are flowing – and the number of ...
Breaking Biology News(10 mins):Ion adsorption matter in biology 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Nanosafety research: The quest for the gold standard 2Nanosafety research: The quest for the gold standard 3
... new study reveals critical molecular events in the origin ... chronic diseases, such as obesity and diabetes, as fat ... said. , The study finds that a hormonal cocktail ... switch in the transition from fat-cell precursors to full-blown ...
... the origin of fat cells. The findings are central ... as fat cells produce hormones critical for metabolic control, ... hormonal cocktail routinely used in the lab induces a ... to full-blown fat, researchers at University of Michigan Life ...
... in 2001 the threat of a larger and more ... tularemia -- became very real. But the ability to ... is still being developed. , In a significant finding, ... demonstrated solar-blind avalanche photodiodes (APDs) that hold promise for ...
Cached Biology News:Key To Stem Cell Transplant Success Is Tricking Immune System 2System Drastically Cuts Down Botulism Detection Time 2Tiny avalanche photodiodes target bioterrorism agents 2
The BD OptEIA Rat TNF-alpha ELISA Kit is for the quantitative determination of TNF-alpha in rat serum, plasma and cell culture supernatant....
Geneticin Selective Antibiotic liquid...
Phosphate-Buffered Saline (PBS) 7.4 (1X) liquid...
with GlutaMAXIL-glutamine...
Biology Products: